4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Improving treatment efficiency via photon optimizer (PO) MLC algorithm for synchronous single‐isocenter/multiple‐lesions VMAT lung SBRT

      other

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Elderly patients with multiple primary or oligometastases (<5 lesions) lesions with associated co‐morbidities may not retain their treatment position for the traditional long SBRT treatment time with individual isocenters for each lesion. Treating multiple lesions synchronously using a single‐isocenter volumetric arc therapy (VMAT) plan would be more efficient with the use of the most recently adopted photon optimizer (PO) MLC algorithm and improve the patient comfort. Herein, we quantified the clinical performance of PO versus its predecessor progressive resolution optimizer (PRO) algorithm for single‐isocenter/multiple‐lesions VMAT lung SBRT.

          Materials and methods

          Fourteen patients with metastatic non‐small‐cell lung cancer lesions (two to five, both uni‐ and bilateral lungs) received a highly conformal single‐isocenter co/non‐coplanar VMAT (2–6 arcs) SBRT treatment plan. Patients were treated with a 6X‐FFF beam and Acuros algorithm with a single‐isocenter placed between/among the lesions, using PO for MLC optimization. Average isocenter to tumor distance was 5.5 ± 1.9 cm. Mean combined PTV derived from 4D‐CT scans was 38.7 ± 22.7 cc. Doses were 54 Gy/50 Gy in 3/5 fractions prescribed to 70%–80% isodose line so that at least 95% of the PTV receives 100% of prescribed dose. Plans were re‐optimized using PRO algorithm. Plans were compared via ROTG‐0915 protocol criteria for target conformity, heterogeneity and gradient indices, and dose to organs‐at‐risk (OAR). Additionally, total number of monitor units (MU), modulation factor (MF) and beam‐on time were compared.

          Results

          All plans met SBRT protocol requirements for target coverage and OAR doses. Comparison of target coverage and dose to the OAR showed no statistical significance between the two plans. PO had 1042 ± 753 ( P < 0.001) less MU than PRO resulting in a beam‐on time of about 0.75 ± 0.5 min ( P < 0.001) less, on average. For similar dose distribution, a significant reduction of beam delivery complexity was observed with PO (average MF = 3.7 ± 0.7) vs PRO MLC algorithm (average MF = 4.4 ± 1.3) ( P < 0.001).

          Conclusions

          PO MLC algorithm improved treatment efficiency without compromising plan quality when compared to PRO algorithm for single‐isocenter/multi‐lesions VMAT lung SBRT. Shorter beam‐on time can potentially reduce intrafraction motion errors and improve patient compliance. PO MLC algorithm is recommended for future clinical lung SBRT plan optimization.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?

          To review treatment outcomes for stereotactic body radiotherapy (SBRT) in medically operable patients with Stage I non-small-cell lung cancer (NSCLC), using a Japanese multi-institutional database. Between 1995 and 2004, a total of 87 patients with Stage I NSCLC (median age, 74 years; T1N0M0, n=65; T2N0M0, n=22) who were medically operable but refused surgery were treated using SBRT alone in 14 institutions. Stereotactic three-dimensional treatment was performed using noncoplanar dynamic arcs or multiple static ports. Total dose was 45-72.5 Gy at the isocenter, administered in 3-10 fractions. Median calculated biological effective dose was 116 Gy (range, 100-141 Gy). Data were collected and analyzed retrospectively. During follow-up (median, 55 months), cumulative local control rates for T1 and T2 tumors at 5 years after SBRT were 92% and 73%, respectively. Pulmonary complications above Grade 2 arose in 1 patient (1.1%). Five-year overall survival rates for Stage IA and IB subgroups were 72% and 62%, respectively. One patient who developed local recurrences safely underwent salvage surgery. Stereotactic body radiotherapy is safe and promising as a radical treatment for operable Stage I NSCLC. The survival rate for SBRT is potentially comparable to that for surgery. Copyright © 2011 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            AAPM TG 158: Measurement and calculation of doses outside the treated volume from external-beam radiation therapy.

            The introduction of advanced techniques and technology in radiotherapy has greatly improved our ability to deliver highly conformal tumor doses while minimizing the dose to adjacent organs at risk. Despite these tremendous improvements, there remains a general concern about doses to normal tissues that are not the target of the radiation treatment; any "nontarget" radiation should be minimized as it offers no therapeutic benefit. As patients live longer after treatment, there is increased opportunity for late effects including second cancers and cardiac toxicity to manifest. Complicating the management of these issues, there are unique challenges with measuring, calculating, reducing, and reporting nontarget doses that many medical physicists may have limited experience with. Treatment planning systems become dramatically inaccurate outside the treatment field, necessitating a measurement or some other means of assessing the dose. However, measurements are challenging because outside the treatment field, the radiation energy spectrum, dose rate, and general shape of the dose distribution (particularly the percent depth dose) are very different and often require special consideration. Neutron dosimetry is also particularly challenging, and common errors in methodology can easily manifest as errors of several orders of magnitude. Task Group 158 was, therefore, formed to provide guidance for physicists in terms of assessing and managing nontarget doses. In particular, the report: (a) highlights major concerns with nontarget radiation; (b) provides a rough estimate of doses associated with different treatment approaches in clinical practice; (c) discusses the uses of dosimeters for measuring photon, electron, and neutron doses; (d) discusses the use of calculation techniques for dosimetric evaluations; (e) highlights techniques that may be considered for reducing nontarget doses; (f) discusses dose reporting; and (g) makes recommendations for both clinical and research practice.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.

              To report clinical and dosimetric factors predictive of radiation pneumonitis (RP) in patients receiving lung stereotactic body radiation therapy (SBRT) from a series of 240 patients. Of the 297 isocenters treating 263 patients, 240 patients (n=263 isocenters) had evaluable information regarding RP. Age, gender, current smoking status and pack-years, O2 use, Charlson Comorbidity Index, prior lung radiation therapy (yes/no), dose/fractionation, V5, V13, V20, Vprescription, mean lung dose, planning target volume (PTV), total lung volume, and PTV/lung volume ratio were recorded. Twenty-nine patients (11.0%) developed symptomatic pneumonitis (26 grade 2, 3 grade 3). The mean V20 was 6.5% (range, 0.4%-20.2%), and the average mean lung dose was 5.03 Gy (0.547-12.2 Gy). In univariable analysis female gender (P=.0257) and Charlson Comorbidity index (P=.0366) were significantly predictive of RP. Among dosimetric parameters, V5 (P=.0186), V13 (P=.0438), and Vprescription (where dose=60 Gy) (P=.0128) were significant. There was only a trend toward significance for V20 (P=.0610). Planning target volume/normal lung volume ratio was highly significant (P=.0024). In multivariable analysis the clinical factors of female gender, pack-years smoking, and larger gross internal tumor volume and PTV were predictive (P=.0094, .0312, .0364, and .052, respectively), but no dosimetric factors were significant. Rate of symptomatic RP was 11%. Our mean lung dose was <600 cGy in most cases and V20<10%. In univariable analysis, dosimetric factors were predictive, while tumor size (or tumor/lung volume ratio) played a role in multivariable and univariable and analysis, respectively. Copyright © 2013 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                damodar.pokhrel@uky.edu
                Journal
                J Appl Clin Med Phys
                J Appl Clin Med Phys
                10.1002/(ISSN)1526-9914
                ACM2
                Journal of Applied Clinical Medical Physics
                John Wiley and Sons Inc. (Hoboken )
                1526-9914
                20 September 2019
                October 2019
                : 20
                : 10 ( doiID: 10.1002/acm2.v20.10 )
                : 201-207
                Affiliations
                [ 1 ] Medical Physics Graduate Program University of Kentucky Lexington KY USA
                [ 2 ] Department of Radiation Medicine University of Kentucky Lexington KY USA
                Author notes
                [*] [* ] Author to whom correspondence should be addressed. Damodar Pokhrel

                E‐mail: damodar.pokhrel@ 123456uky.edu ; Telephone: (859) 323‐7599; Fax: (859) 257‐4931.

                Article
                ACM212721
                10.1002/acm2.12721
                6806472
                31538721
                d34c8606-a2a5-4d7f-9f36-614eab0d9b5a
                © 2019 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 20 June 2019
                : 15 August 2019
                : 25 August 2019
                Page count
                Figures: 4, Tables: 2, Pages: 7, Words: 4877
                Categories
                Technical Note
                Technical Note
                Custom metadata
                2.0
                October 2019
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.0 mode:remove_FC converted:23.10.2019

                lung sbrt,mlc,photon optimizer,single‐isocenter/multi‐lesions,vmat

                Comments

                Comment on this article